

Friday, February 14

1:00 PM - 6:00 PM Registration

The
Canal
Club
Foyer
Heritage
1/2/Hall

1:00 PM - 6:00 PM Exhibitor Move-In

1:30 PM - 4:30 PM Pre-Course: Advancing Innovation, Collaboration, and Clinical Excellence in Advanced Cancer Care
The session will highlight the roles of advanced practice providers in the specialty of Surgical Oncology, enhance clinical knowledge of advanced cancer therapies, and provide structured opportunities for interprofessional networking. Attendees will gain a comprehensive Understanding of how APPs contribute to the multidisciplinary care team, utilizing their clinical expertise and knowledge of advanced cancers to enhance outcomes in patient care.

Key highlights of the Advanced Practice Providers Pre-Course 2025 include:

- In-depth presentations on the diverse responsibilities and contributions of APPs in the management of complex cancers
- Expert-led interdisciplinary sessions showcasing the latest advancements in cancer management and innovative treatment modalities
- Interactive case studies designed to deepen clinical expertise and emphasize the role of APPs in the delivery of quality advanced cancer care
- Insightful discussion exploring the evolving scope of practice and emerging opportunities for APPs in this field of practice
- Panel discussions that facilitate the exchange of ideas, the sharing of best practices, and collaborative problem-solving among providers
- Structured networking opportunities to promote the building of collaborative relationships that support ongoing learning, professional development, and scholarship

Join us for this enriching pre-course to advance your clinical practice, stay abreast of the latest innovations in advanced cancer therapies, and connect with fellow advanced practice professional in Surgical Oncology dedicated to excellence in cancer care.

Upon completion of this session, participants should gain strategies to:

- Identify the roles of the advanced practice provider in the delivery of comprehensive cancer care in the clinical specialty of Surgical Oncology.
- Describe the current evidence-based therapies associated with the management of advanced cancer.
- Discuss opportunities to facilitate ongoing professional development and promote interdisciplinary collaboration in clinical practice and research.

1:30 - 2:00 p.m. Keynote Presentation
Michael E. Lidsky, MD

2:00 - 2:30 p.m. Interdisciplinary Collaboration in the Surgical Management of
Peritoneal Surface Malignancies
Heritage 3/4/5

Saturday, February 15

7:00 AM - 7:30 AM Breakfast Heritage
1/2/Hall

7:00 AM - 3:00 PM Exhibits Heritage
1/2/Hall

7:00 AM - 3:30 PM Registration The Canal
Club Foyer

7:15 AM - 7:30 AM Opening Remarks Orangedale
Ballroom

7:30 AM - 9:00 AM Abstract Presentations Orangedale
Ballroom

9:00 AM - 10:00 AM Symposium: Multimodal Management of Unresectable Colorectal
Liver Metastases Orangedale
Ballroom
Presentations covering modern multimodal management options for
patients with initially unresectable colorectal liver metastases

Upon completion of this session, participants should gain strategies to:

- Plan sequencing of treatment options to include regional and locally ablative therapies such as HAI, IRE, and SBRT.
- Understand the emerging data for histotripsy as treatment for liver metastases.
- Understand the current and evolving indications and criteria for liver transplant for patients with unresectable liver metastases.

	9:00 - 9:12 a.m.	IRE for Unresectable Colorectal Liver Metastases <i>Kevin C. Soares, MD</i>	
	9:12 - 9:24 a.m.	HAI for Unresectable Colorectal Liver Metastases <i>Chandrashekar Padmanabhan, MD</i>	
	9:24 - 9:36 a.m.	Histotripsy and SBRT for Unresectable Colorectal Liver Metastases <i>Clifford S. Cho, MD</i>	
	9:36 - 9:48 a.m.	Liver Transplant for Unresectable Colorectal Liver Metastases <i>Eve Simoneau, MD, PhD</i>	
	9:48 - 10:00 a.m.	Discussion Q&A <i>Panel</i>	
10:00 AM - 10:30 AM	Networking Refreshment Break		Heritage 1/2/Hall
10:30 AM - 12:00 PM	Chair Assembly 10:30 - 10:45 a.m. <i>Chair Lecture</i>		Orangedale Ballroom
	10:45 - 11:30 a.m. <i>Keynote Address: Dr. Marth Zeiger</i>		
	11:30 a.m. - 12:00 p.m. <i>Keynote TalkBack</i>		
12:00 PM - 1:00 PM	Industry Spotlight Presentations		Heritage 1/2/Hall
	12:10 - 12:25 p.m. Industry Spotlight Session 1 (Non-CME) <i>Company</i>		
	12:30 - 12:45 p.m. Industry Spotlight Session 2 (Non-CME) <i>Company</i>		
12:00 PM - 1:00 PM	Lunch Break		Heritage 1/2/Hall
1:00 PM - 2:00 PM	Abstract Presentations		Orangedale Ballroom
2:05 PM - 3:35 PM	Workshop: Management of Hepatic Artery Infusion Pump Therapy-Related Complications (Non-CME) This session will be a case-based discussion of commonly and uncommonly encountered complications related to HAI pump therapy with providing expert opinion and experience on diagnosis, workup, and management of these difficult scenarios. Session will conclude with a panel discussion.		Orangedale Ballroom
	Upon completion of this session, participants should gain strategies to:		
	• Understand the diagnosis, workup, and management of HAI pump pocket complications • Understand the diagnosis, workup, troubleshooting, and management of device or catheter-related complications • Understand the diagnosis, workup, and management of arterial or perfusion-related complications/issues related to HAI therapy • Understand the diagnosis, workup, and management of FUDR- or systemic therapy-related toxicity, including biliary sclerosis and hepatotoxicity		
	2:05 - 2:20 p.m.	HAI Pump Pocket Complications and Management <i>TBD</i>	
	2:20 - 2:35 p.m.	Device and Catheter-Related Complications and Troubleshooting <i>Laleh Melstrom, MD</i>	
	2:35 - 2:50 p.m.	Diagnosis and Management of Arterial Complications and Perfusion Problems <i>Michael Cavnar, MD</i>	
	2:50 - 3:05 p.m.	Biliary Sclerosis and Hepatotoxicity: Pump and Systemic Considerations <i>J. Eva Selfridge</i>	

3:05 - 3:35 p.m. Panel discussion & cases – “I wish I knew this before starting a pump program...”

Panel

2:05 PM - 3:35 PM	Workshop: Palliative Surgery in Advanced Cancer (Non-CME) This session will focus on the treatment of patients with advanced stage cancer that are not candidates for curative-intent therapy. Specific topics covered will be: goals of therapy other than cure and how to discuss these with patients, systemic therapy options for patients with incurable disease, and when surgery is appropriate in the palliative setting. Upon completion of this session, participants should gain strategies to: • Compassionately communicate and establish clear and realistic goals of care with patients who have incurable disease • Explore systemic therapy options for patients with incurable disease, including standard therapies, targeted therapies, and clinical trials • Understand when surgery may be appropriate in the palliative setting, both for symptom control and for disease control 2:05 - 2:07 p.m. Introduction <i>Jula Veerapong, MD; Kaitlyn J. Kelly, MD</i> 2:07 - 2:27 p.m. Palliative Care: Goals of Care Discussions and Timing <i>TBD</i> 2:27 - 2:47 p.m. Surgical Palliation Options <i>Bridget Fahy, MD</i> 2:47 - 3:07 p.m. Navigating Systemic Therapy Options <i>Robert Krouse, MD</i> 3:07 - 3:35 p.m. Case Reviews & Panel Discussion <i>Panel</i>	Heritage 3/4/5
Sunday, February 16		
7:00 AM - 7:30 AM	Breakfast	Heritage 1/2/Hall
7:00 AM - 4:00 PM	Exhibits	Heritage 1/2/Hall
7:00 AM - 5:00 PM	Registration	The Canal Club Foyer
7:30 AM - 9:00 AM	Abstract Presentations	Orangedale Ballroom
9:00 AM - 10:00 AM	Symposium: Cytoreduction for Gastric, Small Bowel, and Pancreas This session will review the role of cytoreduction and HIPEC in patients with gastric cancer, small bowel, and pancreatic cancer peritoneal malignancies. Speakers will review case presentations and their experience in these disease sites. There will be opportunity for audience participation via live poll regarding management in specific case scenarios as well as questions to facilitate engagement. Upon completion of this session, participants should gain strategies to: • Understand the role of cytoreduction and HIPEC in patients with gastric cancer and peritoneal metastases • Understand the role of cytoreduction and HIPEC in patients with small bowel adenocarcinoma and peritoneal metastases • Identify patient selection criteria for cytoreduction and HIPEC in pancreatic cancer 9:00 - 9:20 a.m. Gastric Cancer Case Presentations <i>Brian D. Badgewell, MD, MS</i> 9:20 - 9:40 a.m. Small Bowel Case Presentations <i>Oliver Eng, MD</i> 9:40 - 10:00 a.m. Pancreas Case Presentations <i>Travis E. Grotz, MD, FSSO</i>	Orangedale Ballroom
10:00 AM - 10:30 AM	Networking Refreshment Break	Heritage 1/2/Hall

10:30 AM - 12:00 PM	Abstract Presentations	Orangedale Ballroom
12:00 PM - 1:00 PM	Lunch Break	Heritage 1/2/Hall
12:00 PM - 1:00 PM	Industry Spotlight Presentations	Heritage 1/2/Hall
	12:10 - 12:25 p.m. Industry Spotlight Session 1 (Non-CME) <i>Company</i>	
	12:30 - 12:45 p.m. Industry Spotlight Session 2 (Non-CME) <i>Company</i>	
1:00 PM - 2:30 PM	Workshop: Strategic Clinical Trial Design and Implementation for Advanced Cancers (Non-CME) This workshop is designed for surgeons and researchers seeking to broaden their understanding of clinical trial and execution in the context of advanced cancers. The workshop will equip participants with the knowledge necessary to address the issues that are unique to clinical trials for patients with advanced cancers (GI, Sarcoma, and Melanoma). The focus is on addressing the unique challenges associated with clinical trials in advanced cancers, from the initiation phase through to the execution of correlative studies. Participants will gain insights into the nuances of clinical trial organization, including investigator-initiated studies and cooperative group trials. The workshop will cover funding mechanisms, optimal endpoint selection, and the integration of correlative science to enhance trial outcomes. By the end of the session, attendees will have a foundation of what is necessary in clinical trial planning, enabling them to initiate clinical trials in their practice. Upon completion of this session, participants should gain strategies to: • Understand foundational principles of clinical trial designs specific to surgeons who manage advanced cancers. • Explore the structure and organization of institutional and national surgical clinical trials and their application in cancer research. • Identify and assess funding sources for clinical trials. • Develop strategies for selecting appropriate endpoints to ensure meaningful results. • Integrate correlative science effectively.	
	1:00 - 1:15 p.m.	Considerations of Clinical Trial Design for Advanced Cancer Therapies <i>Beth Helmink, MD, PhD; Thinzar Lwin, MS</i>
	1:15 - 1:35 p.m.	Navigating Cooperative Groups for Trials Utilizing Advancing Cancer Therapies <i>Shishir K. Maithel, MD, FACS, FSSO</i>
	1:35 - 1:40 p.m.	Discussion Q&A <i>Panel</i>
	1:40 - 2:00 p.m.	How to Fund Your Trial? <i>Maheswari Senthil, MD</i>
	2:00 - 2:05 p.m.	Discussion Q&A Orangedale Ballroom
	2:30 PM - 4:00 PM	Workshop: How to Build an Advanced Therapies Program (Non-CME) This will be a workshop focused on the operational aspects of setting up advanced therapies programs for melanoma, including regional perfusion, injectable therapies, and adoptive cellular therapies. The workshop will emphasize elements of program development including Orangedale Ballroom

Preliminary Program

elements of a multidisciplinary team, considerations for accreditation, logistics/resources, financial considerations, partnerships with industry, and associated research programs.

Upon completion of this session, participants should gain strategies to:

- Develop a multidisciplinary team for advanced therapies
- Recognize the operational and financial considerations in starting an advanced therapies program
- Organize a research program in association with advanced therapies clinical program

2:30 - 2:45 p.m. Regional
Perfusion
*Jonathan Zager,
MD*

2:45 - 3:00 p.m. Adoptive Cell
Therapy
*Michael E.
Egger, MD,
MPH*

3:00 - 3:15 p.m. Intralesional
Therapy
*David Ollila,
MD*

3:15 - 4:00 p.m. Discussion
Q&A
Panel

2:30 PM - 4:00 PM	Abstract Presentations: PSM	Heritage 3/4/5
4:30 PM - 6:00 PM	Meet the Professors Reception	Laguna Lawn & Heritage Patio

Monday, February 17

7:00 AM - 7:30 AM	Breakfast	Heritage 1/2/Hall
7:00 AM - 11:00 AM	Exhibits	Heritage 1/2/Hall
7:00 AM - 12:00 PM	Registration	The Canal Club Foyer
7:30 AM - 8:30 AM	Abstract Presentations	Orangedale Ballroom
8:30 AM - 9:30 AM	Symposium: Management of Regionally Advanced and Metastatic Disease when Systemic Therapy Fails The treatment of regionally advanced and metastatic melanoma has rapidly progressed over the last decade with the development of immune checkpoint inhibitors and targeted therapy with BRAF/MEK inhibitors. Unfortunately, the majority of patients with regionally advanced or metastatic disease carry intrinsic resistance	Orangedale Ballroom

Preliminary Program

or will develop acquired resistance to these systemic therapies. Novel strategies to improve responses include upfront immunotherapy for resectable disease (neoadjuvant), adoptive T-cell therapies (clonal T-cell effectors) and oncolytic viral vectors to stimulate immunogenicity or direct targeting of tumor cells. Each of these approaches may be synergistic with the others and may provide windows for surgical intervention in these high-risk settings.

Upon completion of this session, participants should gain strategies to:

- Understand the role and current clinical data on neoadjuvant immunotherapy in regionally advanced melanoma.
- Understand the state of the science of adoptive T-cell therapy and current data that led to recent US FDA approval of TIL for melanoma.
- Describe the role of oncolytic viruses in melanoma and the latest developments in this intralesional strategy.

8:30 - 8:32 a.m.	Introduction <i>Sonia Cohen, MD, PhD;</i> <i>Richard Essner, MD</i>
8:32 - 8:47 a.m.	Neoadjuvant: Update on Trials, Including Nadina Georgia Beasley, MD, MHSc
8:47 - 9:02 a.m.	TIL: Standard of Care vs Trial Experience <i>Amanda Kirane, MD, FACS, FSSO</i>
9:02 - 9:17 a.m.	Updates on TVEC/Oncolytic Viruses <i>Ashley M. Holder, MD</i>
9:17 - 9:30 a.m.	Discussion Q&A <i>Panel</i>

9:30 AM - 10:00 AM	Networking Refreshment Break	Heritage 1/2/Hall
10:00 AM - 11:00 AM	Abstract Presentations	Orangedale Ballroom
11:00 AM - 12:00 PM	Abstract Presentations	Orangedale Ballroom



© Copyright 2024. All Rights Reserved.